Thermo Fisher Scientific inked a deal with Janssen Biotech, part of Johnson & Johnson, to co-develop a companion diagnostic for cancer. The diagnostic test will support global clinical trial enrollment.
Indianapolis-based Eli Lilly announced the FDA’s Oncologic Drugs Advisory Committee voted 6-5 in favor of Cyramza (ramucirumab) plus erlotinib as a potential treatment for patients with untreated metastatic EGFR-positive non-small cell lung cancer (NSCLC).
Oncology Innovation A Q&A with Kantar’s Stephanie Hawthorne, Vice President of Oncology and Specialty Therapeutics Oncology is one of the most exciting areas in healthcare today, as novel therapies continue to emerge that move forward our molecular understanding of the disease and offer effective treatment advances. In 2019, there were a variety of key developments […]
Working with a new class of drugs called G12C KRAS inhibitors, the Francis Crick Institute and Institute of Cancer Research developed product combos to stay ahead of drug-resistant tumors.
Bristol-Myers Squibb released pooled efficacy and safety results from the Phase III CheckMate -017 and CheckMate -057 trials in patients with previously treated advanced NSCLC.
Roche Holding AG priced the company’s personalized cancer treatment Rozlytrek at about $17,050 per month, nearly half of the monthly price of a rival drug from Bayer AG and Eli Lilly and Co. that was approved during 2018.
Humira’s dominance continues as the world’s top-selling prescription product as the biologic therapy is the first drug to exceed $20 billion in annual global sales.
Pfizer Inc. announced that the European Commission approved Vizimpro (dacomitinib), a tyrosine kinase inhibitor, as monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations.
Bristol-Myers Squibb Company announced results from pooled analyses of survival data from four studies (CheckMate -017, -057, -063 and -003; n=664) in patients with previously treated advanced non-small cell lung cancer (NSCLC) who were treated with Opdivo (nivolumab).
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.